Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons ar	are required to respond to a collection of information unless it contains a valid OMB control number.			
Substitute for form 1449/PTO	Complete if Known			
	Application Number	10/552,568		
INFORMATION DISCLOSURE	Filing Date	August 2, 2006		
STATEMENT BY APPLICANT	First Named Inventor	Kishore		
(Use as many sheets as necessary)	Art Unit	1651		
(ose as many sinces as necessary)	Examiner Name	Susan M. Hanley		
Sheet 1 of 1	Attorney Docket Number	21101.0040U2		

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	,
nitials* No.¹ the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>	
		PARKE et al. Multiple organ dysfunction syndrome. Inflammopharmacology, Vol.11, No.1, pages 87-95 (2003).	
		GABRIEL et al. High-dose recombinant human EPO stimulates reticulocyte production in patients with multiple organ dysfunction syndrome. J. of Trauma 44(2):361-7 (Feb. 1998).	
		Office Action (U.S. Application Serial No. 11/791,287), Mailed Aug. 18, 2010.	

	Examiner		Date		
	Signature	U.	Considered		
SEVAMINED: Initial if reference considered whether as not eletion is in conferences with MDED 600. Describe through eletion if not in conferences and not					

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

I Applicant's unique criation designation number (coptonal). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 19.8 The information is required to obtain or retain a benefit by the public which is to fee and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gentlering preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the inclined used any comments on the supplication of the completed application form to the USPTO. There will vary depending upon the inclined used any comments on the Trademark Office P.O. Box. 1450. Alexandris, W. 22313-1450. DNOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O., Box. 1450. Alexandris, W. AZ2313-1450.